Gsk (GSK) Cash & Equivalents (2009 - 2026)

Gsk's Cash & Equivalents history runs 18 years deep, the most recent figure standing at $4.2 billion for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 13.23% year-over-year to $4.2 billion; the TTM figure through Jun 2026 stood at $4.2 billion (down 13.23% YoY), while the FY2025 annual figure was $4.5 billion, down 9.46% from the prior year.
• Cash & Equivalents for Q2 2026 stood at $4.2 billion, down from $4.6 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $8.1 billion in Q2 2022, with the low at $512.6 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $4.2 billion (2022), against an average of $4.3 billion.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents slumped 92.19% in 2022, then jumped 585.32% in 2023.
• Gsk's Cash & Equivalents stood at $4.4 billion in 2022, then dropped by 16.55% to $3.6 billion in 2023, then jumped by 36.31% to $5.0 billion in 2024, then declined by 9.03% to $4.5 billion in 2025, then declined by 7.8% to $4.2 billion in 2026.
• Business Quant data shows GSK's Cash & Equivalents at $4.2 billion in Q2 2026, $4.6 billion in Q1 2026, and $4.5 billion in Q4 2025.